Institution identification

PURI

https://redirect.ema.europa.eu/resource/3331112

Institution ID

3331112

Institution full name and acronym

Parc de Salut Mar Barcelona (PSMAR)

Institution countries

Spain

Type of institution

Hospital/Clinic/Other health care facility

Institution role

Data holder

ENCePP partner

No
Institution details
Experience with collecting data directly from individual patients or respondents:
Yes
Interest in carrying out research that is funded by pharmaceutical companies:
Yes

Contact

Studies conducted by the institution

Assessment of the safety of LABAs in asthma in routine care by combining healthcare databases and direct patient follow-up (ASTRO-LAB)
CHARACTERISATION OF PROTEOMIC PROFILES PREDICTIVE OF HEPATOTOXICITY ASSOCIATED WITH ANTI-TUBERCULOSIS DRUGS: A PILOT STUDY
DARWIN EU® - Background rates of serious adverse events to contextualise safety assessments in clinical trials and non-interventional studies in adolescent and adult patients with severe asthma
DARWIN EU® Multiple myeloma: patient characterisation, treatments and survival in the period 2012-2022
DARWIN EU® Overall survival in patients with locally advanced or metastatic non-small cell lung cancer treated with selected immunotherapies as first line of treatment
DARWIN EU® Treatment patterns of drugs used in adult and paediatric population with systemic lupus erythematosus
Hidroxicloroquine and cloroquine safety profile in patients with SARS-COV-2 infection (COVID-19) (SEHISACoV-2)
Observational study to evaluate the potential effects of biological, biosimilar, and targeted synthetic disease-modifying antirheumatic drugs in the appearance of symptoms compatible with COVID-19 infection (PreCOVIDMar)
Real-world characteristics, management and outcomes of subjects screened or diagnosed with COVID-19 in Spain (COVID-19 REAL)
RISK OF AGRANULOCYTOSIS ASSOCIATED WITH THE USE OF DRUGS
Spanish Registry of Systemic Treatments in Psoriasis (Biobadaderm)